Zevra Therapeutics (ZVRA) former CFO equity awards vest on exit

Rhea-AI Filing Summary

Zevra Therapeutics former CFO & Treasurer Clifton R. LaDuane reported equity transactions tied to his departure on December 31, 2025. On that date, 140,667 shares of common stock were issued at $0 upon vesting of previously granted restricted stock units and performance stock units. After this issuance, he held 192,028 common shares.

Also on December 31, 2025, 48,513 common shares were withheld at $8.96 per share to cover withholding taxes related to the vesting, leaving him with 143,515 common shares beneficially owned directly. The filing shows 86,667 and 34,000 restricted stock units and 20,000 performance stock units converting into common stock, with all such units fully vested and accelerated upon his departure, and no derivative units remaining.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clifton R. LaDuane

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/31/2025		M		140,667(1)	A	$0	192,028	D
Common Stock	12/31/2025		F		48,513(2)	D	$8.96	143,515	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(3)	12/31/2025		M			86,667	(4)	(4)	Common Stock	86,667	$0	0	D
Restricted Stock Unit	(3)	12/31/2025		M			34,000	(4)	(4)	Common Stock	34,000	$0	0	D
Performance Stock Unit	(5)	12/31/2025		M			20,000	(4)	(4)	Common Stock	20,000	$0	0	D

Explanation of Responses:

1. Shares issued upon vesting of restricted stock units and performance stock units on December 31, 2025.

2. Shares withheld to cover withholding taxes for the vested restricted stock units and performance stock units.

3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

4. The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025.

5. Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

	/s/ R. LaDuane Clifton	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ZVRA report for Clifton R. LaDuane on December 31, 2025?

On December 31, 2025, Clifton R. LaDuane reported the issuance of 140,667 shares of Zevra Therapeutics common stock at $0 from vesting of restricted and performance stock units, and a withholding of 48,513 shares at $8.96 to cover taxes.

How many ZVRA shares does Clifton R. LaDuane own after the reported Form 4 transactions?

Following the reported transactions on December 31, 2025, Clifton R. LaDuane beneficially owns 143,515 shares of Zevra Therapeutics common stock directly.

What types of equity awards vested for ZVRAs former CFO on December 31, 2025?

The filing shows vesting of restricted stock units and performance stock units. Specifically, 86,667 and 34,000 restricted stock units and 20,000 performance stock units converted into common stock.

Why were ZVRA restricted stock units and performance stock units accelerated for Clifton R. LaDuane?

The filing states that vesting of all restricted stock units and performance stock units was accelerated upon his departure from the company on December 31, 2025.

How were taxes handled on the vested ZVRA equity awards for the former CFO?

The document notes that 48,513 common shares were withheld to cover withholding taxes related to the vested restricted stock units and performance stock units, at a price of $8.96 per share.

Does Clifton R. LaDuane still hold any ZVRA restricted or performance stock units after these transactions?

No. The filing shows that after the December 31, 2025 transactions, the reported balances for the restricted stock units and performance stock units are 0, indicating no remaining derivative units.